Khodijah Khodijah
Faculty of Medicine, State University of Malang

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

Reconciling Contradictory Findings: In Silico Evaluation of Annonacin’s Antimalarial Efficacy and Safety Anindya Zerlina Tsaqif; Khodijah Khodijah; Fahrizal Ryuzen Prayogi; Moh Mirza Nuryady; Kiky Martha Ariesaka
Sains Medika: Jurnal Kedokteran dan Kesehatan Vol 16, No 2 (2025): December 2025
Publisher : Faculty of Medicine, Universitas Islam Sultan Agung (UNISSULA), Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30659/sainsmed.v16i2.39412

Abstract

Introduction. With the increasing resistance to existing antimalarial therapies, the discovery of new drugs has become urgent. Annona muricata contains phenolic compounds with antioxidant potential and bioactive properties, including annonaceous acetogenins, which exhibit cytotoxicity, raising safety concerns. Conversely, other studies have shown significant antimalarial activity from A. muricata extracts without observed toxicity, suggesting its potential as a lead compound for malaria treatment. This inconsistency calls for further investigation, particularly through in silico analyses, to clarify the interactions between these compounds and key malaria targets. Aim. This study employs in silico methods to explore Annonacin’s binding affinity to malaria proteins, PfDHODH and PfLDH, and evaluates its toxicity and bioavailability. Methods. Molecular docking was conducted using Molegro Virtual Docker (MVD) version 6.0 to assess Annonacin’s binding interactions with PfDHODH and PfLDH. Toxicity was analyzed using ProTox-II, focusing on cytotoxicity and LD50 value. Pharmacokinetic properties, including gastrointestinal absorption and adherence to Lipinski’s rule of five, were evaluated using SwissADME. Results. Docking results revealed that Annonacin forms stable complexes with both proteins, suggesting strong inhibitory potential. However, toxicity analysis highlighted significant cytotoxic effects, with an LD50 of 400 mg/kg placing Annonacin in Toxicity Class IV, indicating ingestion risks. Pharmacokinetic analysis revealed challenges such as low gastrointestinal absorption and a violation of Lipinski’s rule due to high molecular weight. Conclusion. These findings suggest Annonacin has antimalarial potential, but its development is hindered by safety concerns and pharmacokinetic limitations. Further optimization is needed to balance efficacy with safety, providing a foundation for future research and development.
In Silico Docking and ADME-Tox evaluation of annonacin : Addressing contradictions in antimalarial evidence against PfDHODH and PfLDH Anindya Zerlina Tsaqif; Khodijah Khodijah; Fahrizal Ryuzen Prayogi; Moh Mirza Nuryady; Kiky Martha Ariesaka
Sains Medika: Jurnal Kedokteran dan Kesehatan Vol. 16 No. 2 (2025): December 2025
Publisher : Faculty of Medicine, Universitas Islam Sultan Agung (UNISSULA), Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30659/sainsmed.v16i2.39412

Abstract

The rise of resistance to current antimalarial therapies highlights the urgent need for novel drug candidates.Annona muricata contains phenolic compounds, particularly annonaceous acetogenins, known for theirbioactive properties and cytotoxicity. This study investigates the binding affinity of Annonacin to themalaria target proteins PfDHODH and PfLDH and assesses its toxicity and pharmacokinetic propertiesusing in silico methods. Molecular docking was performed using Molegro Virtual Docker (MVD) version6.0 to explore Annonacin’s binding interactions with PfDHODH and PfLDH. Toxicity was evaluatedusing ProTox-II, focusing on cytotoxicity and LD50 values. Pharmacokinetic parameters, includinggastrointestinal absorption and compliance with Lipinski’s Rule of Five, were analysed using SwissADME.Docking analyses indicated stable complexes of Annonacin with both PfDHODH and PfLDH, suggestingstrong inhibitory potential. Toxicity evaluation revealed significant cytotoxic effects, with an LD50 of400 mg/kg, placing Annonacin in Toxicity Class IV, indicating risk upon ingestion. Pharmacokineticassessments identified challenges, including low gastrointestinal absorption and a violation of Lipinski’srule due to Annonacin’s high molecular weight. Annonacin demonstrates notable antimalarial potential;however, its development is limited by safety issues and pharmacokinetic constraints. Optimisation effortsare essential to enhance efficacy and safety, laying the groundwork for future research and development.